Evidence map›Paper›PMID 34665317›Full record

ArticleEuropean radiology2022

Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation therapy.

Yoshifumi Noda, Nisanard Pisuchpen, Nathaniel D Mercaldo, Yurie Sekigami, Theodoros Michelakos, Anushri Parakh, Jennifer Y Wo, Motaz Qadan, Cristina Ferrone, Keith D Lillemoe and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in European radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 3 countries.

Yoshifumi NodaDepartment of Radiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, White 270, Boston, MA, 02114, USA.
Nisanard PisuchpenDepartment of Radiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, White 270, Boston, MA, 02114, USA.
Nathaniel D MercaldoDepartment of Radiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, White 270, Boston, MA, 02114, USA.
Yurie SekigamiDepartment of Surgery, Massachusetts General Hospital, Boston, MA, 02114, USA.
Theodoros MichelakosDepartment of Surgery, Massachusetts General Hospital, Boston, MA, 02114, USA.
Anushri ParakhDepartment of Radiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, White 270, Boston, MA, 02114, USA.
Jennifer Y WoDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114-2696, USA.
Motaz QadanDepartment of Surgery, Massachusetts General Hospital, Boston, MA, 02114, USA.
Cristina FerroneDepartment of Surgery, Massachusetts General Hospital, Boston, MA, 02114, USA.
Keith D LillemoeDepartment of Surgery, Massachusetts General Hospital, Boston, MA, 02114, USA.
David P RyanDepartment of Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114-2696, USA.
Jeffrey W ClarkDepartment of Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114-2696, USA.
Carlos Fernandez-Del CastilloDepartment of Surgery, Massachusetts General Hospital, Boston, MA, 02114, USA.
Theodore S HongDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114-2696, USA.
Avinash R KambadakoneDepartment of Radiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, White 270, Boston, MA, 02114, USA. akambadakone@mgh.harvard.edu.
Harvard University · USMassachusetts General Hospital · USGifu University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo derive a CT-based scoring system incorporating arterial involvement and resectability status to predict R0 resection in patients with pancreatic ductal adenocarcinoma (PDAC) undergoing neoadjuvant chemoradiation therapy (CRT).

methodsThis retrospective study included 112 patients with PDAC who underwent dynamic contrast-enhanced CT before and after neoadjuvant CRT. A 5-point score was used to determine arterial involvement (A score; 1 = no involvement, 2 = haziness, 3 = abutment, 4 = encasement, 5 = deformity) and 4-point score evaluating resectability status (R score; 1 = resectable, 2 = borderline resectable [BR] with venous involvement, 3 = BR with arterial involvement, 4 = locally advanced [LA]). A score before and after CRT were summed with R score before and after CRT to compute the AR score (AR

resultsThe AR

conclusionsA composite score which incorporates degree of arterial involvement and resectability status before and after neoadjuvant CRT is associated with R0 resection and discriminates between R0 and R1 resections in PDAC. KEY POINTS: • A scoring system incorporating arterial involvement and resectability status was associated with R0 resection. • AR

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansNeoadjuvant TherapyRetrospective StudiesMultidetector-row computed tomographyNeoadjuvant therapyPancreatic cancer

Identifiers

PMID34665317
OpenAlexW3206159999

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.